Lightnews — Scholar-powered news

Reposted by Syed Mohi Ahmed, MD, PhD

Gregory Riely @rielymd.bsky.social · 16d

Useful trial shows value of supportive measures for amivantamab tolerance (doxycycline or minocycline, clindamycin, chlorhexidine (on nails), and ceramide-based moisturizer www.jto.org/article/S155...

Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial

Amivantamab plus lazertinib significantly improved progression-free and overall survival versus osimertinib in patients with previously untreated, EGFR-mutant advanced NSCLC. EGFR-targeted therapies a...

www.jto.org

1 1 2

Reposted by Syed Mohi Ahmed, MD, PhD

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · Sep 8

At #WCLC25 results of #FLAURA2 showed a 47.5 mo mOS w/ osimertinib+chemo in pts w/ advanced EGFRm+ NSCLC vs 37.6 with osi monotherapy. Benefit seen across subgroups. Longer chemo-free period with combo. #LCSM #LungCancer #NSCLC #oncsky #cansky

1 3

Reposted by Syed Mohi Ahmed, MD, PhD

Pearl Freier @pearlf.bsky.social · Sep 7

The median overall survival of nearly 4 years appears to be the longest benefit ever reported in a global Phase III clinical trial #FLAURA2 in EGFR-mutated advanced lung cancer #WCLC25 #NSCLC #lcsm #medsky #biosky

Pearl Freier @pearlf.bsky.social · Sep 7

AstraZeneca's cancer drug Tagrisso in combination w/ chemotherapy showed median overall survival/OS of nearly 4 yrs in Phase 3 trial #FLAURA2 in EGFR-mutated advanced non-small cell lung cancer. Below is Penn Medicine medical oncologist & #lcsm expert's tweets from #WCLC25 #NSCLC #medsky #biosky

2 3

Reposted by Syed Mohi Ahmed, MD, PhD

NEJM.org @nejm.org · Sep 7

MARIPOSA phase 3 trial: In advanced non–small-cell lung cancer with EGFR mutations, amivantamab–lazertinib led to longer overall survival than osimertinib but was associated with an increased risk of adverse events of grade 3 or higher. nej.md/4p6j53k

#WCLC25 | @iaslc.bsky.social

Kaplan–Meier estimates of overall survival (assessed in an analysis of the time from randomization to death from any cause) among participants who received amivantamab–lazertinib and those who received osimertinib.

5 14

Syed Mohi Ahmed, MD, PhD @smohahm.bsky.social · 27d

NADIM ADJUVANT
#IASLC #WCLC25

Adjuvant Chemoimmunotherapy for Resected Stage IB–IIIA NSCLC

Interim results from the phase III NADIM ADJUVANT trial, presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC), suggest that adjuv...

ascopost.com

1 2

Syed Mohi Ahmed, MD, PhD @smohahm.bsky.social · Aug 12

PFS benefit noted with adagrasib

Vivek Subbiah, MD @viveksubbiah.bsky.social · Aug 11

Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial - The Lancet www.thelancet.com/journals/lan...

Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial

Adagrasib demonstrated a statistically significant improvement in progression-free survival over docetaxel in patients with previously treated KRASG12C-mutated NSCLC, without new safety signals.

www.thelancet.com

1 1 3

Syed Mohi Ahmed, MD, PhD @smohahm.bsky.social · Aug 9

Pop quiz, hot shot ...

a man is standing on a bus holding onto a railing .

ALT: a man is standing on a bus holding onto a railing .

media.tenor.com

1

Syed Mohi Ahmed, MD, PhD @smohahm.bsky.social · Aug 2

"Baseline PSMA-TTV is prognostic for overall survival and predictive for a beneficial effect on overall survival with the addition of [177Lu]Lu-PSMA-617 to enz as first-line treatment for high-risk metastatic CRPC. By contrast, PSMA SUVmean was not prognostic for PSA progression-free survival or OS"

The Lancet Oncology @thelancetoncol.bsky.social · Aug 1

🚨Online today: Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant #prostatecancer in #ENZAp (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial

www.thelancet.com/journals/lan...

1

Syed Mohi Ahmed, MD, PhD @smohahm.bsky.social · Jul 26

Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer | New England Journal of Medicine www.nejm.org/doi/full/10....

Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer | NEJM

On the basis of phase 2 studies, trastuzumab deruxtecan was approved for patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic gastric cancer or gastroesophageal junctio...

www.nejm.org

Reposted by Syed Mohi Ahmed, MD, PhD

IASLC @iaslc.bsky.social · Jul 15

What does the FDA approval of sunvozertinib mean for patients with EGFR exon 20 insertions? In this week’s #LungCancerConsidered, @stephenvliu.bsky.social talks with Dr. Mariam Alexander and Dr. James Chih-Hsin Yang about the newest EGFR-targeted therapy.

🎧 bit.ly/FDAexon20

FDA Approval: Sunvozertinib in EGFR Exon 20 NSCLC | IASLC

In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses EGFR exon 20 insertions and the recently approved targeted therapy for this subset of ...

bit.ly

2 1

Reposted by Syed Mohi Ahmed, MD, PhD

NEJM.org @nejm.org · Jul 25

DESTINY-Gastric04 trial: Patients with HER2-positive metastatic gastric cancer have limited options after trastuzumab-based treatment. New phase 3 data show longer survival with trastuzumab deruxtecan than with standard second-line chemotherapy. nej.md/46HZ7W3

#MedSky #Oncology

Trastuzumab Deruxtecan in HER2-Positive Gastric Cancer | NEJM

Quick Take Video Summary from The New England Journal of Medicine — Trastuzumab Deruxtecan in HER2-Positive Gastric Cancer

nej.md

3 7

Syed Mohi Ahmed, MD, PhD @smohahm.bsky.social · Jul 20

Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer | New England Journal of Medicine www.nejm.org/doi/full/10....

Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer | NEJM

Perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) is a standard therapy for resectable gastric and gastroesophageal junction adenocarcinomas, but recurrence rates remain hig...

www.nejm.org

Syed Mohi Ahmed, MD, PhD @smohahm.bsky.social · Jul 8

Taletrectinib in ROS1+ Non–Small Cell Lung Cancer: TRUST | Journal of Clinical Oncology ascopubs.org/doi/10.1200/...

Taletrectinib in <i>ROS1</i>+ Non–Small Cell Lung Cancer: TRUST

PURPOSETaletrectinib is an oral, potent, CNS-active, selective, next-generation ROS1 tyrosine kinase inhibitor (TKI). We report integrated efficacy and safety from registrational taletrectinib studies...

ascopubs.org

Reposted by Syed Mohi Ahmed, MD, PhD

NEJM.org @nejm.org · Jun 20

Beamion LUNG-1 trial: Safe, effective, oral therapies are needed for patients with HER2-mutant non–small-cell lung cancer. Research findings on the oral, irreversible, HER2-selective tyrosine kinase inhibitor zongertinib are summarized in a new Quick Take video. nej.md/3HETKwj

#MedSky

An illustration of zongertinib for treating patients with HER2-mutant non–small-cell lung cancer.

3 4

Reposted by Syed Mohi Ahmed, MD, PhD

NEJM.org @nejm.org · Jun 18

In the KEYNOTE-689 phase 3 trial, the addition of neoadjuvant and adjuvant pembrolizumab to standard care improved event-free survival among participants with locally advanced head and neck cancer without affecting surgical outcomes. Full trial results: nej.md/45X0Nuc

#MedSky #Oncology

Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer | NEJM

The benefit of the addition of perioperative pembrolizumab to standard care with surgery and adjuvant therapy for patients with locally advanced head and neck squamous-cell carcinoma (HNSCC) is unc...

nej.md

1 3 8

Reposted by Syed Mohi Ahmed, MD, PhD

NEJM.org @nejm.org · Jun 2

In high-risk cutaneous squamous-cell carcinoma, adjuvant cemiplimab prolonged disease-free survival and reduced recurrence risk as compared with placebo. No new safety concerns with cemiplimab were seen. Full C-POST phase 3 trial results: nej.md/45kvdWR

#ASCO25 @ascocancer.bsky.social

2 4

Reposted by Syed Mohi Ahmed, MD, PhD

NEJM.org @nejm.org · Jun 2

DeLLphi-304: Among patients with relapsed small-cell lung cancer after the failure of platinum-based chemotherapy, tarlatamab therapy led to a greater overall and progression-free survival benefit over chemotherapy, with fewer severe adverse events. nej.md/3YWiy8O

#ASCO25

3 4

Reposted by Syed Mohi Ahmed, MD, PhD

NEJM.org @nejm.org · Jun 2

In non–small-cell lung cancer, three cycles of neoadjuvant nivolumab plus chemotherapy improved 5-year overall survival over chemotherapy alone, with variation according to pathological response. Full CheckMate 816 phase 3 trial results: nej.md/4k6Wlxj

#ASCO25 @ascocancer.bsky.social

4 10

Reposted by Syed Mohi Ahmed, MD, PhD

American Society of Clinical Oncology @ascocancer.bsky.social · Jun 2

Just presented at #ASCO25: Initial DESTINY-Breast09 results show 1L treatment w/ T-DXd + pertuzumab extends PFS by > 1 year compared w/ SOC THP: dailynews.ascopubs.org/do/destiny-b... #ASCODailyNews #BreastCancer #bcsm @danafarber.bsky.social @danafarbernews.bsky.social

1 3

Reposted by Syed Mohi Ahmed, MD, PhD

NEJM.org @nejm.org · Jun 3

In newly diagnosed myeloma, ASCT showed no benefit over chemotherapy in patients without postinduction measurable residual disease, and tandem ASCT was not more effective than single ASCT in those with postinduction MRD. Full MIDAS trial results: nej.md/4mkaecR

#ASCO25

2 3

Syed Mohi Ahmed, MD, PhD @smohahm.bsky.social · Jun 2

statistically and clinically significant OS benefit at 5 y for a resectable solid tumor. Pts with pCR with neoadjuvant NIVO + chemo had a ~90% reduction in their risk of death by 5 y compared with those without pCR.

Syed Mohi Ahmed, MD, PhD @smohahm.bsky.social · Jun 2

Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816.

(Due for release on June 2)

meetings.asco.org/abstracts-pr...

Program Guide – ASCO Meeting Program Guide

meetings.asco.org

Syed Mohi Ahmed, MD, PhD @smohahm.bsky.social · Jun 2

IRONMAN validating the poor prognosis of mHSPC with PSA>0.2 after 6-12 months ADT-ARPI and these patients could be targeted for intensification in future trials. PSA<0.02 at 6-12 m defines the best prognosis and may be of interest for de-intensification strategies.

meetings.asco.org/abstracts-pr...

Program Guide – ASCO Meeting Program Guide

meetings.asco.org

Syed Mohi Ahmed, MD, PhD @smohahm.bsky.social · Jun 2

Randomized, double-blind, Phase 3 trial, CAN-2409 significantly reduced the risk of PrCa recurrence or death when added to SoC EBRT+/- ADT.

CAN-2409: replication-defective adenovirus encoding the HSV-tk gene that, when combined with valacyclovir (prodrug), results in immunogenic cell death

Syed Mohi Ahmed, MD, PhD @smohahm.bsky.social · Jun 2

NIAGARA and ctDNA
- ctDNA+ status at pre-RC was associated with non-pCR.
- Perioperative Durva provided an EFS benefit to both pts with ctDNA+ and ctDNA− status at baseline
- similar trend was observed with DFS based on ctDNA status post-RC

meetings.asco.org/abstracts-pr...

Program Guide – ASCO Meeting Program Guide

meetings.asco.org

Reposted by Syed Mohi Ahmed, MD, PhD

Jose Tapia @tapiajc.bsky.social · Apr 27

Looking forward to #ASCO25. I tried to summarise it, but there’s some really exciting new data.

#Bladder new ADCs strategies, pt selection, ctDNA, non-UC subtypes, RT + IO.
#Kidney biomarkers, new TKI & HIFi, nccRCC
#Prostate new drugs, pt selection, aggressive variants.

1